Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05940753
Other study ID # 15954
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 13, 2023
Est. completion date May 1, 2023

Study information

Verified date July 2023
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a cross-sectional study in the form of a flash mob study, in which an inventory will be made on 13 and 14 March 2023 of the willingness to travel of oncology patients in the participating hospitals. Patients who have an appointment with an internist-oncologist or oncology specialist nurse at the outpatient clinic or by telephone and patients who come to day treatment unit for medical oncology are asked to participate. Willingness to travel is examined by means of a survey, in which a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey.


Recruitment information / eligibility

Status Completed
Enrollment 5000
Est. completion date May 1, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Medical oncology patients with an appointment in the out-patient clinic or day treatment unit on 13 or 14 march 2023 - Medical oncology patients with an (video) call appointment in the out-patient clinic on 13 or 14 march 2023 Exclusion criteria: - Patients in the inpatients oncology unit - Medical oncology patients with no appointment on 13 or 14 march 2023

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Survey about travel willingness regarding cancer treatment and follow-up
No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Travel willingness How far is the oncological patient willing to travel for his/her systemic treatment or follow-up? 1 day
Secondary Facilitating and inhibiting factors for willingness to travel What are facilitating and inhibiting factors in patients' willingness to travel? 1 day
Secondary Which patient characteristics are associated with willingness to travel? Which patient characteristics are associated with willingness to travel? (age, type of cancer, curative/palliative treatment, distance to nearest hospital) 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases